Clinical Trial Update: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

View source ↗

Summary

This real-world study evaluates the combination of camrelizumab and apatinib mesylate for unresectable hepatocellular carcinoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Meng Chao Hepatobiliary Hospital of Fujian Medical University | Conditions: Hepatocellular Carcinoma | Status: RECRUITING